Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-nr4z6 Total loading time: 0 Render date: 2024-05-01T14:53:20.209Z Has data issue: false hasContentIssue false

Chap. 31 - ENDOCRINOLOGIC EMERGENCIES IN DERMATOLOGY

Published online by Cambridge University Press:  07 September 2011

Margaret T. Ryan
Affiliation:
Riddle Memorial Hospital
Vincent Savarese
Affiliation:
Jefferson Medical College of Thomas Jefferson University
Serge A. Jabbour
Affiliation:
Jefferson Medical College of Thomas Jefferson University
Ronni Wolf
Affiliation:
Kaplan Medical Center, Rehovot, Israel
Batya B. Davidovici
Affiliation:
Kaplan Medical Center, Rehovot, Israel
Jennifer L. Parish
Affiliation:
Jefferson Medical College of Thomas Jefferson University
Lawrence Charles Parish
Affiliation:
Jefferson Medical College of Thomas Jefferson University
Get access

Summary

ENDOCRINE AND METABOLIC DISEASES, besides affecting other organs, can result in changes in cutaneous function and morphology and can lead to a complex symptomatology. Dermatologists may see some of these skin lesions first, either before the endocrinologist, or even after the internist or specialist has missed the right diagnosis. Because some skin lesions might reflect a life-threatening endocrine or metabolic disorder, identifying the underlying disorder is important, so that patients can receive corrective rather than symptomatic treatment.

In this section, we review a few endocrine and metabolic disorders in which patients may present to the dermatologist with various skin lesions and in which the diagnosis of the underlying condition must be made in a timely fashion before the patient ends up with complications that could be fatal.

HYPERPIGMENTATION AND ADDISON DISEASE

Addison disease, or primary adrenal insufficiency, can be caused by either infiltrative disorders that invade the adrenal cortex or by destructive disorders that attack the adrenal cells. In either etiology, the adrenal cortex is unable to produce and secrete adequate amounts of glucocorticoid and mineralocorticoid hormones. The most common etiology of Addison disease used to be tuberculous granulomatous disease, but with declining infection rates in the developed world, the most common cause of Addison disease today is autoimmune destruction of the adrenal glands. Other less common causes of Addison include other granulomatous fungal infections (histoplasmosis, coccidiomycosis), metastatic carcinoma infiltration of the adrenals, or bilateral adrenal hemorrhage.

Type
Chapter
Information
Emergency Dermatology , pp. 298 - 312
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Nieman, LK, Turner, MLC. Addison's disease. Clin Dermatol. 2006; 24:276–80.CrossRefGoogle ScholarPubMed
Dunlop, D.Eighty-six cases of Addison's disease. BMJ. 1963; 5362:887–91.CrossRefGoogle Scholar
Kim, SS, Brody, KH. Dehydroepiandrosterone replacement in Addison's disease. Eur J Obstet Gynecol Reprod Biol. 2001; 97:96–7.CrossRefGoogle ScholarPubMed
Jabbour, SA.Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol. 2003; 4(5):315–31.CrossRefGoogle ScholarPubMed
Grinspoon, SK, Biller, BM. Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab. 1994; 79:923–31.Google ScholarPubMed
Oelkers, W, L'age, M. Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement. Klin Wochenschr.1976; 54:607–12.CrossRefGoogle ScholarPubMed
Libè, R, Barbetta, L, Dall'Asta, C, et al. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. J Endocrinol Invest. 2004; 27:736–41.CrossRefGoogle ScholarPubMed
Parker, CM, Hanke, CW, Madura, JA, Liss, EC. Glucagonoma syndrome: case report and literature review. J Dermatol Surg Oncol. 1984; 10:884–9.CrossRefGoogle ScholarPubMed
Chastain, MA.The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci. 2001; 321:306–20.CrossRefGoogle ScholarPubMed
Stone, SP, Buescher, LS. Life-threatening paraneoplastic cutaneous syndromes. Clin Dermatol. 2005; 23(3):301–6.CrossRefGoogle ScholarPubMed
Tierny, EP, Badger, J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. Med Gen Med. 2004; 6:4–13.Google Scholar
Marinkovich, MP, Botella, R, Datloff, J, Sangueza, OP. Necrolytic migratory erythema without glucagonoma in patients with liver disease. J Am Acad Dermatol. 1995; 32:604–9.CrossRefGoogle ScholarPubMed
Smith, AP, Doolas, A, Staren, ED. Rapid resolution of necrolytic migratory erythema after glucagonoma resection. J Surg Oncol. 1996; 61:306–9.3.0.CO;2-3>CrossRefGoogle ScholarPubMed
Wynik, D, Hammond, PJ, Bloom, SR. The glucagonoma syndrome. Clin Dermatol. 1993; 11:93–7.CrossRefGoogle Scholar
Tomssetti, P, Migliori, M, Gullo, L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol. 1998; 93:1468–71.CrossRefGoogle Scholar
Altimari, AF, Bhoopalam, N, O'Dorsio, T, et al. Use of a somatostatin analog (SMS 201–995) in the glucagonoma syndrome. Surgery. 1986; 100:989–96.Google ScholarPubMed
Appetecchia, M, Ferretti, E, Carducci, M, et al. Malignant glucagonoma. New options of treatment. J Exp Clin Cancer Res. 2006; 25:135–9.Google Scholar
Shepherd, ME, Raimer, SS, Tyring, SK, et al. Treatment of necrolytic migratory erythema in glucagonoma syndrome. J Am Acad Dermatol. 1991; 25:925–8.CrossRefGoogle ScholarPubMed
Ai, J, Leonhardt, JM, Heymann, WR. Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations. J Am Acad Dermatol. 2003; 48:641–62.CrossRefGoogle ScholarPubMed
Fatourechi, V, Bartley, GB, Eghbali-Fatourechi, GZ, et al. Graves' dermopathy and acropachy are markers of severe Graves' ophthalmopathy. Thyroid. 2003; 13:1141–4.CrossRefGoogle ScholarPubMed
Shong, YK, Kim, JA. Vitiligo in autoimmune thyroid disease. Thyroidology. 1991; 3:89–91.Google ScholarPubMed
Ross, DS.Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease. Endocrinol Metab Clin North Am. 2001; 30:245–64.CrossRefGoogle ScholarPubMed
Cooper, DS. Antithyroid drugs. N Engl J Med. 2005; 352:905–17.CrossRefGoogle ScholarPubMed
Lely, AJ, Herder, WW. Carcinoid syndrome: diagnosis and medical management. Arq Bras Endocrinol Metab. 2005; 49:850–60.CrossRefGoogle ScholarPubMed
Jabbour, SA, Davidovici, BB, Wolf, R. Rare syndromes. Clin Dermatol. 2006; 24:299–316.CrossRefGoogle ScholarPubMed
Modlin, IM, Kidd, M, Latich, I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005; 128:1717–51.CrossRefGoogle ScholarPubMed
Kulke, MH, Mayer, RJ. Medical progress: carcinoid tumors. N Engl J Med. 1999; 340:858–68.CrossRefGoogle Scholar
Bell, HK, Poston, GJ, Vora, J, Wilson, NJ. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol. 2005; 152:71–5.CrossRefGoogle ScholarPubMed
Sanduleanu, S, Bruïne, A, Stridsberg, M, et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest. 2001; 31:802–11.CrossRefGoogle ScholarPubMed
Carling, RS, Degg, TJ, Allen, KR, et al. Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease. Ann Clin Biochem. 2002; 39:577–82.CrossRefGoogle ScholarPubMed
Modlin, IM, Latich, I, Zikusoka, M, et al. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol. 2006; 40:572–82.CrossRefGoogle ScholarPubMed
Caplin, ME, Buscombe, JR, Hilson, AJ, et al. Carcinoid tumor. Lancet. 1998; 352:799–805.CrossRefGoogle Scholar
Kvols, LK, Moertel, CG, O'Connell, MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986; 315:663–6.CrossRefGoogle ScholarPubMed
Brockow, K.Urticaria pigmentosa. Immunol Allergy Clin N Am. 2004; 24:287–316.CrossRefGoogle ScholarPubMed
Escribano, L, Akin, C, Castells, M, et al. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002; 81:677–90.Google ScholarPubMed
Soter, NA. Mastocytosis and the skin. Hematol Oncol Clin North Am. 2000; 14:537–55.CrossRefGoogle Scholar
Horny, HP, Sillaber, C, Menke, D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998; 22:1132–40.CrossRefGoogle ScholarPubMed
Valent, P, Horny, HP, Escribano, L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001; 25:603–25.CrossRefGoogle ScholarPubMed
Valent, P, Akin, C, Escribano, L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007; 37:435–53.CrossRefGoogle ScholarPubMed
Schwartz, LB, Sakai, K, Bradford, TR, et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest. 1995; 96:2702–10.CrossRefGoogle ScholarPubMed
Keyzer, JJ, Monchy, JG, Doormaal, JJ, Voorst Vader, PC. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med. 1983; 309:1603–5.CrossRefGoogle ScholarPubMed
Schwartz, LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res. 2001; 25:553–62.CrossRefGoogle ScholarPubMed
Vella Briffa, D, Eady, RA, James, MP, et al. Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa. Br J Dermatol. 1983; 109:67–75.CrossRefGoogle ScholarPubMed
Ahmed, I, Goldstein, B. Diabetes mellitus. Clin Dermatol. 2006; 24:237–46.CrossRefGoogle ScholarPubMed
Grandis, JR, Branstetter, BF, Yu, VL. The changing face of malignant (necrotizing) external otitis: clinical, radiological, and anatomic correlations. Lancet Infect Dis. 2004; 4:34–9.CrossRefGoogle Scholar
,American Diabetes Association. Clinical practice recommendations 2008. Diabetes Care. 2008; 31:s1–s110.Google Scholar
Hermanns-Le, T, Scheen, A, Pierard, GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol. 2004; 5:199–203.CrossRefGoogle ScholarPubMed
Fisher, ER, Danowski, TS. Histologic, histochemical, and electron microscopic features of the shin spots of diabetes mellitus. Am J Clin Pathol. 1968; 50:547–54.CrossRefGoogle ScholarPubMed
Iwasaki, T, Kahama, T, Houjou, S, et al. Diabetic scleroderma and scleroderma-like changes in a patient with maturity onset type diabetes of young people. Dermatology. 1994; 188:228–31.CrossRefGoogle Scholar
Petzelbauer, P, Wolff, K, Tappeiner, G. Necrobiosis lipoidica: treatment with systemic corticosteroids. Br J Dermatol. 1992; 126:542–5.CrossRefGoogle ScholarPubMed
Elder, GH.Porphyria cutanea tarda. Semin Liver Dis. 1998; 18:67–75.CrossRefGoogle ScholarPubMed
Elder, GH, Roberts, AG, Salamanca, RE.Genetics and pathogenesis of human uroporphyrinogen decarboxylase defects. Clin Biochem. 1989; 22:163–8.CrossRefGoogle ScholarPubMed
Cripps, DJ, Peters, HA, Gocman, A, Dogramici, I. Porphyria turcica due to hexachlorobenzene: a 20–30 year follow-up study on 204 patients. Br J Dermatol. 1984; 111:413–22.CrossRefGoogle ScholarPubMed
Bleiberg, J, Wallen, M, Brodkin, R, Applebaum, IL. Industrially acquired porphyria. Arch Dermatol. 1964; 80:793–7.CrossRefGoogle Scholar
Bleasel, NR, Varigos, GA. Porphyria cutanea tarda. Australas J Dermatol. 2000; 41:197–206.CrossRefGoogle ScholarPubMed
Fodinger, M, Sunder-Plassmann, G. Inherited disorders of iron metabolism. Kidney Int Suppl. 1999; 69:S22–34.CrossRefGoogle ScholarPubMed
Lambrecht, RW, Thapar, M, Bonkovsky, HL. Genetic aspects of porphyria cutanea tarda. Semin Liver Dis. 2007; 27:99–108.CrossRefGoogle ScholarPubMed
Cortes, JM, Oliva, H, Paradinas, FJ, Hernandez-Guio, C. The pathology of the liver in porphyria cutanea tarda. Histopathology. 1980; 4:471–85.CrossRefGoogle ScholarPubMed
Badiu, C, Cristofor, D, Voicu, D, Coculescu, M. Diagnostic traps in porphyria: case report and literature review. Rev Med Chir Soc Med Nat Iasi. 2004; 108:584–91.Google ScholarPubMed
Kordac, V, Jirsa, M, Kotal, P, et al. Agents affecting porphyrin formation and secretion: implications for porphyria cutanea treatment. Semin Hematol. 1989; 26:16–23.Google ScholarPubMed
Finn, LS, Zhang, M, Chen, SH, Scott, CR. Severe type II Gaucher disease with ichthyosis, arthrogryposis and neuronal apoptosis: molecular and pathological analyses. Am J Med Genet. 2000; 91:222–6.3.0.CO;2-#>CrossRefGoogle ScholarPubMed
Tayebi, N, Stone, DL, Sidransky, E. Type 2 Gaucher disease: an expanding phenotype. Mol Genet Metab. 1999; 68:209–19.CrossRefGoogle Scholar
Fujimoto, A, Tayebi, N, Sidransky, E. Congenital ichthyosis preceding neurologic symptoms in two siblings with type 2 Gaucher disease. Am J Med Genet. 1995; 59:356–68.CrossRefGoogle Scholar
Sidransky, E, Fartasch, M, Lee, RE, et al. Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease. Pediatr Res. 1996; 39:134–41.CrossRefGoogle ScholarPubMed
Elias, PM, Williams, ML, Holleran, WM, et al. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res. 2008; 49:697–714.CrossRefGoogle ScholarPubMed
Marsh, NL, Elias, PM, Holleran, WM. Glucosylceramides stimulate murine epidermal hyperproliferation. J Clin Invest. 1995; 95:2903–9.CrossRefGoogle ScholarPubMed
Mohrenschlager, M, Braun-Falco, M, Ring, J, Abeck, D. Fabry disease: recognition and management of cutaneous manifestations. Am J Clin Dermatol. 2003; 4:189–96.CrossRefGoogle ScholarPubMed
Hurwitz, S.Clinical pediatric dermatology. 2nd ed. Philadelphia: WB Saunders; 1993.Google Scholar
Orteu, CH, Jansen, T, Lidove, O, et al. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol. 2007; 157:331–7.CrossRefGoogle ScholarPubMed
Frost, P, Tamala, Y, Spaeth, GL. Fabry's disease: glycolipid lipidosis. Histochemical and electron microscopic studies of two cases. Am J Med. 1966; 40:618–27.CrossRefGoogle ScholarPubMed
Schiffman, R, Kopp, JB, Austin, HA, et al. Enzyme replacement therapy in Fabry disease. JAMA. 2001; 285:2743–9.CrossRefGoogle Scholar
Eng, CM, Guffon, N, Wilcox, WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry's disease. N Engl J Med. 2001; 345:9–16.CrossRefGoogle ScholarPubMed
Maverakis, E, Fung, MA, Lynch, PJ, et al. Acrodermatitis enteropathica and an overview of zinc metabolism. J Am Acad Dermatol. 2007; 56:116–24.CrossRefGoogle ScholarPubMed
Prasad, AS.Discovery of human zinc deficiency and studies in an experimental human model. Am J Clin Nutr. 1991; 53:403–12.CrossRefGoogle Scholar
Perafan-Riveros, C, Franca, LF, Alves, AC, Sanches, JA. Acrodermatitis enteropathica: case report and review of the literature. Pediatr Dermatol. 2002; 19(5):426–31.CrossRefGoogle ScholarPubMed
Dillaha, CJ, Lorincz, AL. Enteropathic acrodermatitis (Danbolt): successful treatment with diodoquin (diiodohydroxyquinoline). AMA Arch Dermatol Syphilol. 1953; 67:324–6.Google Scholar
Danks, DM.Diagnosis of trace metal deficiency–with emphasis on copper and zinc. Am J Clin Nutr. 1981; 34:278–80.CrossRefGoogle ScholarPubMed
Naber, TH, Baadenhuysen, H, Jansen, JB, et al. Serum alkaline phosphatase activity during zinc deficiency and long-term inflammatory stress. Clin Chim Acta. 1996; 249:109–27.CrossRefGoogle ScholarPubMed
Sandstrom, B, Cederblad, A, Lindblad, BS, Lonnerdal, B. Acrodermatitis enteropathica, zinc metabolism, copper status, and immune function. Arch Pediatr Adolesc Med. 1994; 148:980–5.CrossRefGoogle ScholarPubMed
Mancini, AJ, Tunnessen, WW. Picture of the month. Acrodermatitis enteropathica-like rash in a breast-fed, full-term infant with zinc deficiency. Arch Pediatr Adolesc Med. 1998; 152:1239–40.Google Scholar
Neldner, KH, Hambidge, KM. Zinc therapy of acrodermatitis enteropathica. N Engl J Med. 1975; 292:879–82.CrossRefGoogle ScholarPubMed
Prendiville, JS, Manfredi, LN. Skin signs of nutritional disorders. Semin Dermatol. 1992; 11:88–97.Google ScholarPubMed
Heath, ML, Sidbury, R. Cutaneous manifestations of nutritional deficiency. Curr Opin Pediatr. 2006; 18:417–22.CrossRefGoogle ScholarPubMed
Barthelemy, H, Chouvet, B, Cambazard, F. Skin and mucosal manifestations in vitamin deficiency. J Am Acad Dermatol. 1986; 15:1263–74.CrossRefGoogle ScholarPubMed
Bleasel, NR, Stapleton, KM, Lee, MS, Sullivan, J. Vitamin A deficiency phrynoderma: due to malabsorption and inadequate diet. J Am Acad Dermatol. 1999; 41:322–4.CrossRefGoogle ScholarPubMed
Maronn, M, Allen, DM, Esterly, NB. Phrynoderma: a manifestation of vitamin A deficiency?…the rest of the story. Pediatric Dermatol. 2005; 22:60–3.CrossRefGoogle Scholar
Roe, DA. Riboflavin deficiency: mucocutaneous signs of acute and chronic deficiency. Semin Dermatol. 1991; 10:293–5.Google ScholarPubMed
Friedli, A, Saurat, J. Images in clinical medicine. Oculo-orogenital syndrome–a deficiency of vitamins B2 and B6. N Engl J Med. 2004; 350:1130.CrossRefGoogle ScholarPubMed
Goskowicz, M, Eichenfield, LF. Cutaneous findings of nutritional deficiencies in children. Curr Opin Pediatr. 1993; 5:441–5.Google ScholarPubMed
Price, NM. Vitamin C deficiency. Cutis. 1980; 26:375–7.Google ScholarPubMed
Catalano, PM. Vitamin, C.Arch Dermatol. 1971; 103:537–9.CrossRef
Frias Soriano, L, Lage Vazquez, MA, Maristany, CP, Xandri Graupera, JM, Wouters-Wesseling, W, Wagenaar, L. The effectiveness of oral nutritional supplementation in the healing of pressure ulcers. J Wound Care. 2004; 13:319–22.CrossRefGoogle ScholarPubMed
Hathcock, JN. Vitamins and minerals: efficacy and safety. Am J Clin Nutr. 1997; 66:427–37.CrossRefGoogle ScholarPubMed
Lombaert, A, Carton, H. Benign intracranial hypertension due to A-hypervitaminosis in adults and adolescents. Eur Neurol. 1976; 14:340–50.CrossRefGoogle ScholarPubMed
Tanaka, M, Niizeki, H, Shimizu, S, Miyakawa, S. Photoallergic drug eruption due to pyridoxine hydrochloride. J Dermatol. 1996; 23:708–9.CrossRefGoogle ScholarPubMed
Sherertz, EF. Acneiform eruption due to “megadose” vitamins B6 and B12. Cutis. 1991; 48:119–20.Google ScholarPubMed
Camarasa, JG, Serra-Baldrich, E, Lluch, M. Contact allergy to vitamin B6. Contact Dermatitis. 1990; 23:115.CrossRefGoogle ScholarPubMed
Curhan, GC, Willett, WC, Rimm, EB, Stampfer, MJ. A prospective study of the intake of vitamins C and B6 and the risk of kidney stones in men. J Urol. 1996; 155:1847–51.CrossRefGoogle Scholar
Diplock, AT. Safety of antioxidant vitamins and beta-carotene. Am J Clin Nutr. 1995; 62(6 Suppl):1510S–1516S.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×